Neda Najafi

Neda Najafi

Auto-generated profile, based on publicly available information

Neda Najafi

Department of Nephrology, Hasheminejad Kidney Center, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2025 in Journal of Nephropharmacology
Verified
Journal Article
Open access
PDF file
NNNeda Najafi
Neda Najafi
HSHoushang Sanadgol
Houshang Sanadgol
HAHounaz Akbari
Hounaz Akbari
AKAsal Sadat Karimi
Asal Sadat Karimi
NSNegin Sanadgol
Negin Sanadgol
MVMohsen Vahedi
Mohsen Vahedi
Introduction: The COVID-19 pandemic has highlighted the vulnerability of patients with chronic kidney disease (CKD) to severe complications from the virus. Remdesivir, an antiviral drug initially developed for Ebola, has emerged as a treatment option for COVID-19, yet its safety and efficacy in patients with kidney disease remain under investigation. Objectives: This study aims to evaluate the complications associated with remdesivir in COVID-19 patients who have pre-existing kidney conditions. Patients and Methods: This retrospective cohort study involved 230 COVID-19 patients who were referred to Hasheminejad hospital in Tehran between October 2021 and July 2022, all of whom received a minimum of 100 mg of remdesivir. Participants were categorized based on their history of kidney disease into groups comprising those with CKD, end-stage renal disease (ESRD), and kidney transplant (KT) recipients as well as patients without a history of kidney disease including those with consistently normal kidney function. The study assessed demographic data and laboratory parameters related to liver function, specifically measuring alanine aminotransferase (ALT) and aspartate aminotransferase (AST), along with lactate dehydrogenase (LDH) levels, as well as inflammatory markers, including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), at both baseline and post-treatment intervals. Data were compared between groups using analytical tests. Results: Out of 230 included patients, 145 showed no kidney impairment, while 30 had CKD, 35 had undergone KT, and 20 were ESRD. The results indicated that there were no significant differences in liver enzyme levels (including AST and ALT), inflammatory markers (including CRP and ESR), and LDH, from pre- to post-administration of remdesivir between patients with kidney impairment and those without. Additionally, no differences were found among different kidney impairment groups such as CKD, KT, and ESRD. However, LDH and ESR levels were significantly higher in KT patients compared to those without kidney impairment, raising potential concerns for this population. Conclusion: The findings suggest that remdesivir-related complications concerning liver function, inflammatory markers, and LDH levels did not show significant differences between patients with or without kidney impairment, particular attention should be given to KT recipients due to observed significant increases in LDH and ESR, which may indicate a higher risk of adverse outcomes in this vulnerable population.

11 January 2025 in Journal of Nephropathology
Verified
Journal Article
Open access
FSFereshteh Saddadi
Fereshteh Saddadi
BMBahareh Marghoob
Bahareh Marghoob
NNNeda Najafi
Neda Najafi
HAHounaz Akbari
Hounaz Akbari
MFMohammad Hassan Fallahkohan
Mohammad Hassan Fallahkohan
The co-occurrence of postpartum acute interstitial nephritis (AIN) and myocarditis is a rare but serious complication of pregnancy following HELLP (hemolysis, elevated liver enzymes, and low-platelet) syndrome. We present the case of a 42-year-old woman who developed HELLP syndrome at the 31st week of gestational age. Termination of pregnancy and eight sessions of plasmapheresis were conducted. The patient exhibited acute kidney injury (AKI), dyspnea, bilateral pleural effusion, and 30% left ventricular (LV) ejection fraction. The diagnosis of AIN was established by kidney biopsy, while the post-partum cardiomyopathy (PPCM) was confirmed by cardiac magnetic resonance imaging (CMRI). The AKI and PPCM, in addition to hematologic abnormalities, were successfully resolved with intravenous methylprednisolone, followed by oral prednisolone.